Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QR-01
- Development stage
- Preclinical
- Lead developer
- Orocidin
- Modality
- Peptides
- Administration
- Topical
01
Overview
QR-01 is a therapeutic candidate being developed by Orocidin, a Danish biopharmaceutical company that became a subsidiary of Nordicus Partners Corporation in 2024. The drug is specifically designed for the treatment of periodontitis, a serious gum infection that damages the soft tissue and can destroy the bone that supports teeth. QR-01 is intended for localized administration within the oral cavity to address the underlying bacterial infection and associated inflammation. Following its acquisition, Nordicus Partners has focused on supporting the clinical development of QR-01 and establishing its presence in the United States market.
Beyond the preview
Go deeper on QR-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QR-01.